Press release
Extensive Stage Small Cell Lung Cancer Market Survey Detailed Analysis and Forecast 2023-2031
Extensive Stage Small Cell Lung Cancer Market Size is predicted exhibit a 7.4% CAGR during the forecast period for 2023-2031.
Get a Free Sample Report: https://www.insightaceanalytic.com/request-sample/2276
Extensive Stage Small Cell Lung Cancer Market Report Scope:
Report Attribute Specifications
Growth rate CAGR CAGR of 7.4 % from 2023 to 2031
Quantitative units Representation of revenue in US$ Billion, and CAGR from 2023 to 2031
Historic Year 2019 to 2022
Forecast Year 2023-2031
Report coverage The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends
Segments covered Product and Region
Regional scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia
Competitive Landscape AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Jazz Pharmaceuticals Plc, G1 Therapeutics Inc., Lee's Pharmaceutical Limited, Shanghai Henlius Biotech, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Beigene Ltd.
Extensive stage small cell lung cancer (SCLC) is a rapidly spreading and aggressive form of lung cancer. The limited stage and extensive stage are the two stages of small cell lung cancer (SCLC). Also, it is a difficult disease to treat. Chemotherapy and radiation therapy treatments are used to improve the quality of life.
The American Cancer Society estimates that in 2023, there will be 238,340 new cases of lung cancer and around 127,070 deaths from lung cancer. This will result in increased spread of extensive stage small cell lung cancer. Thereby increasing the demand for better therapeutic options, which could significantly improve the outcome of this disease. However, Immune checkpoint inhibitors are a novel alternative that has just emerged.
Companies engage in strategic activities, such as product launches and developments, to increase their market presence. For instance, in Dec 2021, Shanghai Henlius Biotech, Inc. announced that the first interim analysis met the primary study endpoint of the overall survival (OS) of Phase 3 clinical study (NCT04063163) of its innovative PD-1 inhibitor serplulimab in combination with chemotherapy in previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC).
Geographically, North America is expected to remain at the top in the global extensive stage small cell lung cancer market over the forecast period. According to the American Cancer Society, lung cancer (both small cell and non-small cell) is the second most common cancer in the United States. Thus, the growing prevalence of extensive stage small lung cancer is anticipated to drive the market demand in the future. Moreover, developed healthcare infrastructure and the increasing R&D efforts to improve therapeutic solutions for lung cancer contribute to market growth.
On the other hand, the extensive stage small cell lung cancer market of the Asia-Pacific region is predicted to grow fastest during the projected period. The rising number of lung cancer cases, growing public awareness about cancer, and the increasing government initiatives to improve cancer treatments likely to create new market growth opportunities for the players.
Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2276
The major market players include
• Hoffmann-La Roche Ltd
• AstraZeneca PLC
• Jazz Pharmaceuticals Plc
• G1 Therapeutics Inc.
• Shanghai Henlius Biotech, Inc.
• Lee's Pharmaceutical Limited
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Beigene Ltd.
Key Market Developments
• In January 2023, G1 Therapeutics, Inc. announced the 2023 data readouts from its phase 2 and pivotal phase 3 clinical trials of Trilaciclib for some of the most aggressive and refractory cancers, including metastatic colorectal (mCRC), bladder or urothelial cancer (mUC), and triple negative breast cancer (TNBC).
• In October 2022, G1 Therapeutics, Inc. announced that the company is supporting a Phase 2 investigator initiated study (ISS) of trilaciclib and lurbinectedin in patients with extensive stage small cell lung cancer (ES-SCLC).
• In April 2022, Shanghai Henlius Biotech, Inc. declared that the National Medical Products Administration (NMPA) accepated the New Drug Application (NDA) of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the first-line treatment of extensive stage small cell lung cancer (ES-SCLC). HANSIZHUANG potentially the world's first PD-1 inhibitor for the first-line treatment of SCLC.
• In March 2021, Lee's Pharmaceutical announced its anti-PD-L1 antibody Socazolimab, licensed from Sorrento Therapeutics, and received clearance to start a phase 3 trial as a first-line treatment of extensive-stage small-cell lung cancer.
• In February 2021, G1 Therapeutics, Inc. received U.S. FDA approval for COSELA™ (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
• In March 2020, AstraZeneca received FDA approval for durvalumab (IMFINZI, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Get Specific Chapter/Information From The Report: https://www.insightaceanalytic.com/customisation/2276
Market Segmentation
Global Extensive Stage Small Cell Lung Cancer Market, by Products, 2022-2031 (Value US$ Mn)
• Commercial
• Clinical
Global Extensive Stage Small Cell Lung Cancer Market, by Region, 2022-2031 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Extensive Stage Small Cell Lung Cancer Market, by Country, 2022-2031 (Value US$ Mn)
• U.S.
• Canada
Europe Extensive Stage Small Cell Lung Cancer Market, by Country, 2022-2031 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Extensive Stage Small Cell Lung Cancer Market, by Country, 2022-2031 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Extensive Stage Small Cell Lung Cancer Market, by Country, 2022-2031 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Extensive Stage Small Cell Lung Cancer Market, by Country, 2022-2031 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
> To receive a comprehensive analysis of the prospects for the global Extensive Stage Small Cell Lung Cancer market
> To receive an industry overview and future trends of the Extensive Stage Small Cell Lung Cancer market
> To analyze the Extensive Stage Small Cell Lung Cancer market drivers and challenges
> To get information on the Extensive Stage Small Cell Lung Cancer market size (Value US$ Mn) forecast to 2031
> Significant investments, mergers & acquisitions in the Extensive Stage Small Cell Lung Cancer market industry
For More Information: https://www.insightaceanalytic.com/report/extensive-stage-small-cell-lung-cancer-market-/2276
Other Related Reports Published by InsightAce Analytic:
https://www.insightaceanalytic.com/report/global-multiple-cancer-monoclonal-antibodies-market-/1112
https://www.insightaceanalytic.com/report/global-novel-drug-delivery-systems-in-cancer-therapy-market-/1440
https://www.insightaceanalytic.com/report/global-cancer-biosimilars-market/1078
Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
info@insightaceanalytic.com
North America:
+1 551 226 6109
Asia:
+91 79 72967118
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Extensive Stage Small Cell Lung Cancer Market Survey Detailed Analysis and Forecast 2023-2031 here
News-ID: 3327284 • Views: …
More Releases from Insightace analytic
Digital Pathology Market Report- Expansive Coverage on the Profit Sources
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Pathology Market Size, Share & Trends Analysis Report By Product (Artificial Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma, Academia, Hospitals)- Market Outlook And Industry Analysis 2031"
The global digital pathology market is estimated to reach over USD 2731.95 million by 2031, exhibiting a CAGR of 12.91%…
Digital Health Market Future Trends and Scope Analysis Report
Digital Health Market Size, Share & Trends Analysis Report By Technology (Tele-healthcare, mHealth, Healthcare Analytics, Digital Health Systems), By Component (Software, Hardware, Services), By Region, And Segment Forecasts, 2024-2031
"Digital Health Market" in terms of revenue was estimated to be worth $248.58 billion in 2023 and is poised to reach $1,004.03 billion by 2031, growing at a CAGR of 19.56% from 2023 to 2031, according to a new report by…
Digital Diabetes Management Market Report on the Untapped Growth Opportunities i …
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Diabetes Management Market - (By Devices (Smart Glucose Meters, Continuous Glucose Monitoring Systems, And Smart Insulin Pens, Smart Insulin Pumps/ Closed-Loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps, Obesity & Diet Management Apps), Data Management Software & Platforms And Services), By Device Type (Handheld And Wearable Devices), By End-User(Self/Home Healthcare, Hospitals…
Data Center Liquid Cooling Market Exclusive Trends Analysis with Forecast to 203 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Data Center Liquid Cooling Market Size, Share & Trends Analysis Report By End-User Industry (Financial Services And Insurance (BFSI), Banking, IT And Telecom, Government And Public Sector, Manufacturing, Healthcare, Retail), Data Center (Hyperscale, Colocation, Enterprise) And Solution (Indirect & Direct Cooling)- Market Outlook And Industry Analysis 2031"
The Global Data Center Liquid Cooling Market is estimated…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
